ECS Botanics (ASX:ECS) - Managing Director & Founder, Alex Keach
Managing Director & Founder, Alex Keach
Source: The Examiner
The Market Online - At The Bell

Join our daily newsletter At The Bell to receive exclusive market insights

  • ECS Botanics Holdings’ (ECS) subsidiary Murray Meds has entered into a three-year cannabis supply agreement with an as-yet unnamed Australian cannabinoid company
  • Under the agreement, ECS will the supply THC dried cannabis flower in jars, bulk dried cannabis flower, THC API and medicinal cannabis oil to the unnamed company
  • The minimum spend across the life of the agreement is $750,000 with $500,000 expected in the first year
  • ECS Botanics is down 6.06 per cent, trading at 6.2 cents

ECS Botanics Holdings’ (ECS) subsidiary Murray Meds has entered into a three-year cannabis supply agreement with an as-yet unnamed Australian cannabinoid company.

Murray Meds has a fully licensed medicinal cannabis cultivation facility with permits to produce 3500 kilograms of medicinal cannabis, as well as dried flower, oils and tinctures.

This agreement with the unnamed company is for the supply of THC dried cannabis flower in jars, bulk dried cannabis flower, THC API and medicinal cannabis oil in 30 and 50 millilitre bottles.

The minimum spend across three year agreement is $750,000 with a forecast spend of approximately $500,000 in the first year. However, in accordance with the terms of the agreement, the specific pricing and units remain confidential.

“This is the second supply contract Murray Meds has signed in recent weeks and validates that a low capex and operating medicinal cannabis facility can still meet pharmaceutical quality of the oil and premium priced dry flower market,” said ECS Botanics Managing Director Alex Keach.

“ECS has previously collaborated and worked closely with the customer. We look forward to furthering this relationship and, with the acquisition of Murray Meds, expanding the ECS sales network from our production hubs in Victoria and Tasmania.”

The agreement follows Murray Meds’ supply agreement with London-based pharmaceuticals distribution company The Armour Group for the sale and export of medicinal cannabis oils in the UK and Germany.

ECS Botanics is down 6.06 per cent this morning, trading at 6.2 cents at 9:20 am AEDT.

ECS by the numbers
More From The Market Online

Inoviq closes the gap on blood test results for ovarian cancer

INOVIQ has announced encouraging blood test identification results for ovarian cancer – cancer-positive tests saw a…

Paradigm Biopharma on track to US Phase III osteo program

Paradigm Biopharma has announced its completion of a submission to the US FDA to progress to…

Firebrick Pharma’s US launch of Nasal Spray is nothing to be sneezed at

Australian pharmaceutical developer, Firebrick Pharma (ASX:FRE) has launched its latest product, Nasodine Nasal Spray, in the…